Jianmin Pharmaceutical Group Co Ltd
SSE:600976
Jianmin Pharmaceutical Group Co Ltd
SSE:600976
Price:
35.11
CNY
2.36%
Market Closed
Market Cap:
¥5.4B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Jianmin Pharmaceutical Group Co Ltd
SSE:600976
|
CN |
|
H
|
Hong Kong Technology Venture Co Ltd
SWB:XHNA
|
HK |
|
D
|
Dewhurst Group PLC
LSE:DWHA
|
UK |
|
Actia Group SA
PAR:ALATI
|
FR |
|
B
|
Broncus Holding Corp
HKEX:2216
|
CN |
|
Mercia Asset Management PLC
LSE:MERC
|
UK |
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
IE |
|
C
|
CK Asset Holdings Ltd
SWB:1CK
|
HK |
|
I
|
Idun Industrier AB (publ)
STO:IDUN B
|
SE |
|
Alpha and Omega Semiconductor Ltd
NASDAQ:AOSL
|
US |
|
H
|
Heartflow Inc
NASDAQ:HTFL
|
US |
|
Wing Fung Group Asia Ltd
HKEX:8526
|
HK |
|
C
|
China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062
|
CN |
Multiples-Based Value
The
Multiples-Based Value for
Jianmin Pharmaceutical Group Co Ltd (600976)
under the Base Case is
hidden
CNY.
Compared with the current market price of 35.11 CNY, the stock appears
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Jianmin Pharmaceutical Group Co Ltd Multiples-Based Value
LOCKED
Multiples Across Competitors
Competitors Multiples
Jianmin Pharmaceutical Group Co Ltd Competitors
Jianmin Pharmaceutical Group Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
|
Jianmin Pharmaceutical Group Co Ltd
SSE:600976
|
5.4B CNY | 1.7 | 16.5 | 24.8 | 24.8 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883.9B USD | 13.6 | 42.8 | 28.9 | 30.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
585.2B USD | 6.2 | 21.8 | 15.2 | 18.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.5B GBP | 5.4 | 31.2 | 17.2 | 24.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.7 | 11.6 | 13.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
299.1B USD | 4.6 | 16.4 | 10.1 | 12.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
236.4B CHF | 5.4 | 21.8 | 13.5 | 17.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.3 | 7.6 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
161B USD | 2.6 | 20.7 | 7.9 | 10.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120B USD | 2.5 | 17 | 7.2 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
